XL092 + Pembrolizumab for Oral Squamous Cell Carcinoma

(NEO COMBAT XL Trial)

This trial tests a new combination of treatments for oral squamous cell carcinoma. Researchers aim to determine if adding the experimental drug XL092 to the existing treatment pembrolizumab enhances tumor shrinkage before surgery. They seek participants with surgically removable tumors who meet specific health criteria, such as having a tumor marker of PD-L1 CPS ≥ 1. The goal is to assess whether this combination leads to better outcomes than the standard treatment. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering participants an opportunity to contribute to advancements in cancer therapy.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research has shown that the combination of XL092 and pembrolizumab has been tested for safety in other studies. Pembrolizumab alone treats various cancers and is generally well-tolerated. Common side effects include fatigue, skin rash, and mild digestive issues, while more serious side effects occur less frequently.

Studies have found that combining XL092 with pembrolizumab remains safe, with side effects similar to those of pembrolizumab alone. However, there may be a higher risk of liver-related problems, so trials often monitor liver function.

Researchers are excited about XL092 combined with pembrolizumab for treating oral squamous cell carcinoma because this combination offers a new approach to tackling the cancer. Pembrolizumab is an immunotherapy that helps the immune system recognize and attack cancer cells, while XL092 is a novel tyrosine kinase inhibitor that targets specific proteins involved in cancer cell growth. This dual-action strategy could potentially enhance treatment effectiveness compared to traditional chemotherapy and radiation, which are the standard of care. By combining these mechanisms, the treatment has the potential to improve outcomes for patients with surgically resectable oral cavity squamous cell carcinoma.

Research has shown that pembrolizumab may effectively treat oral cavity squamous cell carcinoma (OCSCC), particularly in patients who respond well to it. Studies have found that pembrolizumab can significantly reduce tumors in some cases. This trial tests a combination of XL092 (zanzalintinib) and pembrolizumab to see if it can further improve results. Early studies suggest that this combination might enhance pembrolizumab's effectiveness in shrinking tumors. The goal is to achieve a higher rate of complete response (no cancer left) or major response (less than 10% of cancer remaining) before surgery.¹²³⁴⁵